HSDT vs. NDRA, TIVC, NUWE, BCEL, PHAS, NAVB, REVB, RNAZ, KRBP, and IONM
Should you be buying Helius Medical Technologies stock or one of its competitors? The main competitors of Helius Medical Technologies include ENDRA Life Sciences (NDRA), Tivic Health Systems (TIVC), Nuwellis (NUWE), Atreca (BCEL), PhaseBio Pharmaceuticals (PHAS), Navidea Biopharmaceuticals (NAVB), Revelation Biosciences (REVB), TransCode Therapeutics (RNAZ), Kiromic BioPharma (KRBP), and Assure (IONM). These companies are all part of the "medical" sector.
ENDRA Life Sciences (NASDAQ:NDRA) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
ENDRA Life Sciences received 215 more outperform votes than Helius Medical Technologies when rated by MarketBeat users. Likewise, 62.67% of users gave ENDRA Life Sciences an outperform vote while only 57.14% of users gave Helius Medical Technologies an outperform vote.
In the previous week, ENDRA Life Sciences and ENDRA Life Sciences both had 5 articles in the media. ENDRA Life Sciences' average media sentiment score of 0.53 beat Helius Medical Technologies' score of 0.21 indicating that Helius Medical Technologies is being referred to more favorably in the news media.
ENDRA Life Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.
Helius Medical Technologies has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Helius Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Helius Medical Technologies has a consensus target price of $54.50, suggesting a potential upside of 2,944.69%. Given ENDRA Life Sciences' higher possible upside, analysts clearly believe Helius Medical Technologies is more favorable than ENDRA Life Sciences.
ENDRA Life Sciences has a net margin of 0.00% compared to ENDRA Life Sciences' net margin of -1,374.22%. Helius Medical Technologies' return on equity of -197.36% beat ENDRA Life Sciences' return on equity.
1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 18.6% of Helius Medical Technologies shares are held by institutional investors. 4.8% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 7.3% of Helius Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Helius Medical Technologies beats ENDRA Life Sciences on 10 of the 15 factors compared between the two stocks.
Get Helius Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSDT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helius Medical Technologies Competitors List
Related Companies and Tools
